Navigation Links
Trubion Announces Presentations at April/May Investor Conferences
Date:4/24/2008

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that executives will present an overview of the company at two upcoming investor conferences in April and May:
-- April 30: Morgan Stanley Global Healthcare Unplugged Conference at The

Ritz-Carlton, 455 Grand Bay Drive in Key Biscayne, FL. Dr. Peter

Thompson, president, CEO and chairman, is scheduled to present at

9:50 a.m. EDT. The presentation will be available via audio Webcast at

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=18.

-- May 13: Bank of America 2008 Health Care Conference at the Four

Seasons, 3960 Las Vegas Blvd S in Las Vegas, NV. Michelle Burris,

senior vice president and chief financial officer, is scheduled to

present at 1:20 p.m. PDT. The presentation will be available via audio

Webcast at

http://www.veracast.com/webcasts/bas/healthcare08/id62101185.cfm.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

For more information, contact:

Trubion Pharmaceuticals, Inc.

Jim DeNike

Senior Director, Corporate Communications

206-838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

617-576-5788

amyp@waggeneredstrom.com TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
5. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
6. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
7. Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
8. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
9. Inverness Medical Innovations Announces First Quarter 2008 Results
10. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
11. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. ... to perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s ...
(Date:10/6/2017)... ... 06, 2017 , ... The HealthTech Venture Network (HTVN) is ... fourth annual Conference where founders, investors, innovative practitioners and collaborators are invited to ... showcasing early stage digital health and med tech companies. , This day-long event ...
(Date:10/5/2017)... YORBA LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is giving back to cancer ... shirt sold in October. , Now through October 31, shoppers can use promo ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):